Catecholaminergic polymorphic ventricular tachycardia

Catecholaminergic polymorphic ventricular tachycardia
Classification and external resources
OMIM	604772 611938
DiseasesDB	33816

Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) is an electrophysiological disorder of the heart that occurs in genetically predisposed individuals. Thought to affect as many as one in ten thousand people, it is estimated to cause 15% of all unexplained sudden cardiac deaths in young people.

First recognized in 1975, the voltage gated ion channel mutation intermittently causes the heart to enter a life threatening state of arrhythmia as response to the natural release of catecholamines. The most common symptom is syncope, which most commonly appears during the first or second decade of life.

Because its symptoms are most prevalent when the body is subjected to intense emotional or physical stress, the condition can elude traditional methods of heart examination such as echocardiogram and resting electrocardiogram.

Signs and symptoms

Syncopal

CPVT may cause exercise-induced ventricular arrhythmias and/or syncope occurring during physical activity or acute emotion, but demonstrates no structural problems of the heart. Ventricular tachycardia may self-terminate or degenerate into ventricular fibrillation, causing sudden death without immediate cardiopulmonary resuscitation. The majority of events occur during childhood and more than 60% of affected individuals will have a first episode of syncope or cardiac arrest by age 20.

Diagnosis

CPVT diagnosis is based on reproducing ventricular arrhythmias during exercise stress testing, syncope occurring during physical activity and acute emotion, and a history of exercise or emotion-related palpitations and dizziness with an absence of structural cardiac abnormalities.+|url=http://cardiovascres.oxfordjournals.org/cgi/content/full/67/3/379%7Caccessdate=2009-02-09 }}</ref>

• The Ryanodine receptor (RYR2) is involved in intracardiac Ca²⁺ handling; Ca²⁺ overload triggers abnormal cardiac activity.
• Calsequestrin (CASQ2) is a calcium buffering protein of the sarcoplasmic reticulum.

Treatment

Medication

Medications to treat CPVT include beta blockers and verapamil.

According to recent research published in Nature Medicine, flecainide inhibits the release of the cardiac ryanodine receptor–mediated Ca²⁺, and is therefore believed to medicate the underlying molecular cause of CPVT in both mice and humans.

Implantable cardioverter-defibrillator

Implantable cardioverter-defibrillators are used to prevent sudden death.

Sympathectomy

In recent reports, left cardiac sympathetic denervation and bilateral thoracoscopic sympathectomy have shown promising results in individuals whose symptoms cannot be controlled by beta blockers.

See also

• Brugada syndrome
• Cardiac arrhythmia
• Long QT syndrome
• Sick sinus syndrome
• Sudden cardiac death

Further reading

• Receptor defects cause inherited disorder CPVT
• Denervation successfully treats catecholaminergic polymorphic ventricular tachycardia
• Screening relatives of sudden-death victims provides likely cause of death and potentially saves lives
• Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) Information sheet - Auckland District Health Board's Cardiac Inherited Disease Registry
• Clinical Data's PGxHealth Division Launches CPVT Cardiac Channelopathy Test - Business Wire
• SADS UK - What is CPVT
• Arrhythmogenesis in CPVT: Lessons Learned from a CPVT Mouse Model

External links

• Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) Information Sheet
• GeneReviews article
• The Hannah Wernke Memorial Foundation

it:Tachicardia ventricolare polimorfa catecolaminergica pl:Wielokształtny częstoskurcz komorowy zależny od katecholamin